FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy

(June 7, 2021) – Medtronic announced receipt of U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead System for Deep Brain Stimulation (DBS) therapy. SenSight™ allows physicians to deliver precise, patient-specific DBS therapy. Click here to learn more about Medtronic and SenSight™.

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.